Wells Fargo initiated coverage on Horizon Pharma with a new price target
$HZNP
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Horizon Pharma with a rating of Overweight and set a new price target of $137.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2022 | $74.00 | Neutral | H.C. Wainwright |
| 8/4/2022 | Outperform → Mkt Perform | SVB Leerink | |
| 6/14/2022 | $139.00 | Buy | UBS |
| 6/6/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 5/23/2022 | $95.00 | Mkt Perform | SVB Leerink |
| 3/15/2022 | $140.00 | Outperform | Oppenheimer |
| 3/2/2022 | $135.00 → $140.00 | Overweight | Morgan Stanley |
| 12/8/2021 | $137.00 | Overweight | Wells Fargo |
H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00
SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform
UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00
15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)
Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the Scheme becoming effective Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that the Irish H